Andrew Combs, EVP, Head of Chemistry at Prelude Therapeutics Inc (PRLD), bought 8,000 shares at $12.12 ($95K) on 2021-12-13, disclosed to the SEC on 2021-12-15.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Several strong factors at once. The rarest rating we give.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.12 | 4,000 | $48K | 51.1% |
| 2 | $11.60 | 4,000 | $46K | 48.9% |
| Total | $11.86 avg | 8,000 | $95K | 100% |
| Filing → |
| PRLD | BUY | 2020-09-29 | $19K | — | Filing → |